TriangleResectable Locally Advanced Head and Neck Squamous Cell CarcinomaNCT07455032
Neoadjuvant CADI-05 + Pembrolizumab
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Cabeza y cuello.
2 estudios de fase 1 reclutando ahora mismo, los actualizados más recientemente primero.
Cabeza y cuello2 estudios
Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06868433
TMV Vaccine With Pembrolizumab
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer